Galectin Therapeutics To Present Update On Its Belapectin Liver Cirrhosis Program At The 20th Edition Of Discovery On Target Meeting, In Boston, September 25-28, 2023
Portfolio Pulse from Benzinga Newsdesk
Galectin Therapeutics, Inc. (NASDAQ:GALT) will present an update on its belapectin liver cirrhosis program at the 20th edition of the Discovery on Target meeting. The presentation will focus on the role of activated macrophages in liver cirrhosis and the potential of belapectin, a galectin-3 inhibitor, in treating the disease. Belapectin is currently in a Phase 2b/3 trial for the prevention of esophageal varices in NASH cirrhosis.
September 26, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Galectin Therapeutics will present an update on its belapectin liver cirrhosis program, which is currently in a Phase 2b/3 trial. The presentation could potentially influence investor sentiment and stock price.
The presentation at the Discovery on Target meeting could potentially influence investor sentiment towards Galectin Therapeutics, depending on the perceived progress and potential of the belapectin liver cirrhosis program. However, without specific details on the update, it's difficult to predict the exact impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100